We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

25 hedge funds and large institutions have $3.42M invested in PDS Biotechnology in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more capital invested

Capital invested by funds: $1.19M → $3.42M (+$2.23M)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0.18% less ownership

Funds ownership: 11.27% → 11.09% (-0.18%)

11% less funds holding

Funds holding: 28 → 25 (-3)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Holders
25
Holders Change
-3
Holders Change %
-10.71%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$349K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$73.2K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$36.5K
4
LNC
Lincoln National Corp
Pennsylvania
+$18.5K
5
IGGA
Iron Gate Global Advisors
Utah
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
WVP
Worth Venture Partners
New Jersey
-$118K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$55K
3
Millennium Management
Millennium Management
New York
-$49K
4
UBS Group
UBS Group
Switzerland
-$28K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$22.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.25M +$349K +313,051 +101%
Federated Hermes
2
Federated Hermes
Pennsylvania
$772K – – –
First Manhattan
3
First Manhattan
New York
$299K – – –
SI
4
Sofinnova Investments
California
$287K – – –
NLVP
5
New Leaf Venture Partners
New York
$236K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$168K +$73.2K +65,773 +363%
Bank of New York Mellon
7
Bank of New York Mellon
New York
$73K -$1 -1 -0%
Two Sigma Advisers
8
Two Sigma Advisers
New York
$66K +$36.5K +32,800 New
IWA
9
Inspirion Wealth Advisors
Illinois
$65K +$10.2K +9,165 +39%
AFM
10
Andesa Financial Management
Pennsylvania
$33K – – –
LNC
11
Lincoln National Corp
Pennsylvania
$33K +$18.5K +16,647 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$30K -$22.4K -20,105 -58%
BlackRock
13
BlackRock
New York
$29K – – –
IGGA
14
Iron Gate Global Advisors
Utah
$27K +$14.7K +13,192 New
Northern Trust
15
Northern Trust
Illinois
$26K +$1.61K +1,449 +13%
WS
16
Wedbush Securities
California
$20K +$11.1K +10,000 New
EIP
17
Ellis Investment Partners
Pennsylvania
$3K – – –
PNC Financial Services Group
18
PNC Financial Services Group
Pennsylvania
$1K – – –
TI
19
tru Independence
Oregon
$1 – – –
WVP
20
Worth Venture Partners
New Jersey
– -$118K -162,000 Closed
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
– -$55K -75,342 Closed
Millennium Management
22
Millennium Management
New York
– -$49K -67,235 Closed
UBS Group
23
UBS Group
Switzerland
– -$28K -38,400 Closed
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
– -$10K -13,281 Closed
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
– -$9K -12,991 Closed
1
2

PDSB Hedge Fund Activity: Q2 2020 in Review

25 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2020, worth a combined $3.42M — up 188% from $1.19M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PDSB and 6 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $349K. The largest seller was Worth Venture Partners, exiting entirely with an estimated $118K sold.

  • 25 institutional investors held PDS Biotechnology (PDSB) as of Q2 2020, down from 28 in Q1 2020.
  • Funds reported $3.42M of PDS Biotechnology stock for Q2 2020, up 188% quarter-over-quarter.
  • 6 funds opened new PDS Biotechnology positions in Q2 2020 and 9 closed out, a net change of -3 holders.
  • The largest PDS Biotechnology buyer in Q2 2020 was Renaissance Technologies, an estimated $349K added.
  • The largest PDS Biotechnology seller in Q2 2020 was Worth Venture Partners, an estimated $118K sold.

Based on aggregated 13F filings for Q2 2020.